Download PDF
Thromb Haemost 2014; 112(03): 503-510
DOI: 10.1160/TH14-01-0064
Blood Coagulation, Fibrinolysis and Cellular Haemostasis
Schattauer GmbH

Indirect comparison meta-analysis of two enoxaparin regimens in patients undergoing major orthopaedic surgery

Impact on the interpretation of thromboprophylactic effects of new anticoagulant drugs
Silvy Laporte
1   EA3065, Université Jean Monnet, Saint-Etienne, France
2   Unité de Recherche Clinique, Innovation, Pharmacologie, Centre hospitalo-universitaire de Saint-Etienne, Hôpital Nord, Saint-Etienne, France
,
Céline Chapelle
2   Unité de Recherche Clinique, Innovation, Pharmacologie, Centre hospitalo-universitaire de Saint-Etienne, Hôpital Nord, Saint-Etienne, France
3   Inserm CIE3, Saint-Etienne, France
,
Laurent Bertoletti
1   EA3065, Université Jean Monnet, Saint-Etienne, France
4   Service de Médecine et Thérapeutique, Centre hospitalo-universitaire de Saint-Etienne, Hôpital Nord, Saint-Etienne, France
,
Jean-Christophe Lega
5   Service de Thérapeutique, Université Claude Bernard Lyon 1, Villeurbanne, France
6   Département de Médecine Interne et Pathologie Vasculaire, Hôpital Lyon Sud, Centre hospitalo-universitaire de Lyon, Pierre-Bénite, France
,
Michel Cucherat
7   UMR CNRS 5558 Evaluation et Modélisation des Effets Thérapeutiques, Université Claude Bernard Lyon 1, Villeurbanne, France
,
Paul J. Zufferey
1   EA3065, Université Jean Monnet, Saint-Etienne, France
2   Unité de Recherche Clinique, Innovation, Pharmacologie, Centre hospitalo-universitaire de Saint-Etienne, Hôpital Nord, Saint-Etienne, France
8   Service d’Anesthésie Réanimation, Centre hospitalo-universitaire de Saint-Etienne, Hôpital Nord, Saint-Etienne, France
,
Jean-Yves Darmon
9   Département Médical, MediBridge, Vélizy, France
,
Patrick Mismetti
1   EA3065, Université Jean Monnet, Saint-Etienne, France
2   Unité de Recherche Clinique, Innovation, Pharmacologie, Centre hospitalo-universitaire de Saint-Etienne, Hôpital Nord, Saint-Etienne, France
4   Service de Médecine et Thérapeutique, Centre hospitalo-universitaire de Saint-Etienne, Hôpital Nord, Saint-Etienne, France
,
the META-EMBOL Group › Author Affiliations Financial support: This work was part of the META-EMBOL project, supported by the Programme Hospitalier de Recherche Clinique 2008, Ministère de la Santé, France.
Further Information

Publication History

Received: 22 January 2014

Accepted after major revision: 08 January 2014

Publication Date:
02 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

Two enoxaparin dosage regimens are used as comparators to evaluate new anticoagulants for thromboprophylaxis in patients undergoing major orthopaedic surgery, but so far no satisfactory direct comparison between them has been published. Our objective was to compare the efficacy and safety of enoxaparin 3,000 anti-Xa IU twice daily and enoxaparin 4,000 anti-Xa IU once daily in this clinical setting by indirect comparison meta-analysis, using Bucher’s method. We selected randomised controlled trials comparing another anticoagulant, placebo (or no treatment) with either enoxaparin regimen for venous thromboembolism prophylaxis after hip or knee replacement or hip fracture surgery, provided that the second regimen was assessed elsewhere versus the same comparator. Two authors independently evaluated study eligibility, extracted the data, and assessed the risk of bias. The primary efficacy outcome was the incidence of venous thomboembolism. The main safety outcome was the incidence of major bleeding. Overall, 44 randomised comparisons in 56,423 patients were selected, 35 being double-blind (54,117 patients). Compared with enoxaparin 4,000 anti-Xa IU once daily, enoxaparin 3,000 anti-Xa IU twice daily was associated with a reduced risk of venous thromboembolism (relative risk [RR]: 0.53, 95% confidence interval [CI]: 0.40 to 0.69), but an increased risk of major bleeding (RR: 2.01, 95% CI: 1.23 to 3.29). In conclusion, when interpreting the benefit-risk ratio of new anticoagulant drugs versus enoxaparin for thromboprophylaxis after major orthopaedic surgery, the apparently greater efficacy but higher bleeding risk of the twice-daily 3,000 anti-Xa IU enoxaparin regimen compared to the once-daily 4,000 anti-Xa IU regimen should be taken into account.

Keywords

Heparin / LMWH - meta-analysis - oral anticoagulants - orthopaedics - venous thrombosis

* Members of the META-EMBOL Group are listed in the online supplementary material (available online at www.thrombosis-online.com).


 

  • References

  • 1 Falck-Ytter Y, Francis CW, Johanson NA. et al. American College of Chest Physicians. Prevention of VTE in orthopaedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (02) Suppl e278S-325S.
    CrossrefPubMedGoogle Scholar
  • 2 Consensus statement. Prevention and treatment of venous thromboembolism. International consensus statement (guidelines according to scientific evidence). Int Angiol 2006; 25: 101-161.
    PubMedGoogle Scholar
  • 3 Samama CM, Gafsou B, Jeandel T. et al. French Society of Anaesthesia and Intensive Care. Guidelines on perioperative venous thromboembolism prophylaxis. Update 2011. Short text. Ann Fr Anesth Reanim 2011; 30: 947-951.
    CrossrefPubMedGoogle Scholar
  • 4 Colwell Jr, CW, Spiro TE, Trowbridge AA. et al. Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am 1994; 76: 3-14.
    CrossrefPubMedGoogle Scholar
  • 5 Higgins JP, Altman DG, Gøtzsche PC. et al. Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. Br Med J 2011; 343: d5928.
    CrossrefPubMedGoogle Scholar
  • 6 Committee for Proprietary Medicinal Products. Guideline on clinical investigation on medicinal products for prophylaxis of high intra- and post-operative venous thromboembolic risk. The European Agency for the Evaluation of Medicinal Products. London, UK,: 15 November 2007. CPMP/EWP/707/98 Rev.1.
    Google Scholar
  • 7 Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 03: 692-694.
    CrossrefPubMedGoogle Scholar
  • 8 Bucher HC, Guyatt GH, Griffith LE. et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997; 50: 683-691.
    CrossrefPubMedGoogle Scholar
  • 9 Lassen MR, Davidson BL, Gallus A. et al. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007; 05: 2368-2375.
    CrossrefPubMedGoogle Scholar
  • 10 Lassen MR, Raskob GE, Gallus A. et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009; 361: 594-604.
    CrossrefPubMedGoogle Scholar
  • 11 RE-MOBILIZE Writing Committee. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009; 24: 1-9.
    CrossrefPubMedGoogle Scholar
  • 12 Turpie AGG, Lassen MR, Davidson BL. et al. RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009; 373: 1673-1680.
    CrossrefPubMedGoogle Scholar
  • 13 Heit JA, Colwell CW, Francis CW. et al. AstraZeneca Arthroplasty Study Group. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. Arch Intern Med 2001; 161: 2215-2221.
    CrossrefPubMedGoogle Scholar
  • 14 Colwell Jr, CW, Berkowitz SD, Davidson BL. et al. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. J Thromb Haemost 2003; 01: 2119-2130.
    CrossrefPubMedGoogle Scholar
  • 15 Bauer KA, Eriksson BI, Lassen MR. et al. Steering Committee of the Pentasaccharide in Major Knee Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001; 345: 1305-1310.
    CrossrefPubMedGoogle Scholar
  • 16 Turpie AG, Bauer KA, Eriksson BI. et al. PENTATHALON 2000 Study Steering Committee. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002; 359: 1721-1726.
    CrossrefPubMedGoogle Scholar
  • 17 Lassen MR, Fisher W, Mouret P. et al. SAVE Investigators. Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE. J Thromb Haemost 2012; 10: 822-832.
    CrossrefPubMedGoogle Scholar
  • 18 Levine MN, Hirsh J, Gent M. et al. Prevention of deep-vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med 1991; 114: 545-551.
    CrossrefPubMedGoogle Scholar
  • 19 Colwell Jr, CW, Spiro TE, Trowbridge AA. et al. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep venous thrombosis after elective knee arthroplasty. Enoxaparin Clinical Trial Group. Clin Orthop Relat Res 1995; 321: 19-27.
    PubMedGoogle Scholar
  • 20 Turpie AG, Levine MN, Hirsh J. et al. A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1986; 315: 925-929.
    CrossrefPubMedGoogle Scholar
  • 21 Leclerc JR, Geerts WH, Desjardins L. et al. Prevention of deep-vein thrombosis after major knee surgery - a randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo. Thromb Haemost 1992; 67: 417-423.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Lassen MR, Raskob GE, Gallus A. et al. ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010; 375: 807-815.
    CrossrefPubMedGoogle Scholar
  • 23 Lassen MR, Gallus A, Raskob GE. et al. ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010; 363: 2487-2498.
    CrossrefPubMedGoogle Scholar
  • 24 Eriksson BI, Dahl OE, Rosencher N. et al. RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 05: 2178-2185.
    CrossrefPubMedGoogle Scholar
  • 25 Eriksson BI, Dahl OE, Rosencher N. et al. RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 949-956.
    CrossrefPubMedGoogle Scholar
  • 26 Eriksson BI, Dahl OE, Huo MH. et al. RE-NOVATE II Study Group. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost 2011; 105: 721-729.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Eriksson BI, Borris LC, Dahl OE. et al,; ODIXa-HIP Study Investigators. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 2006; 114: 2374-2381.
    CrossrefPubMedGoogle Scholar
  • 28 Eriksson BI, Borris LC, Friedman RJ. et al. RECORD 1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-2775.
    CrossrefPubMedGoogle Scholar
  • 29 Lassen MR, Ageno W, Borris LC. et al. RECORD 3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776-2786.
    CrossrefPubMedGoogle Scholar
  • 30 Eriksson BI, Agnelli G, Cohen AT. et al. METHRO III Study Group. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost 2003; 89: 288-296.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Eriksson BI, Agnelli G, Cohen AT. et al. EXPRESS Study Group. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost 2003; 01: 2490-2496.
    CrossrefPubMedGoogle Scholar
  • 32 Eriksson BI, Bauer KA, Lassen MR. et al. Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001; 345: 1298-1304.
    CrossrefPubMedGoogle Scholar
  • 33 Lassen MR, Bauer KA, Eriksson BI. et al. European Pentasaccharide Elective Surgery Study (EPHESUS) Steering Committee. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002; 359: 1715-1720.
    CrossrefPubMedGoogle Scholar
  • 34 Bonneux IM, Bellemans J, Fabry G. Evaluation of wound healing after total knee arthroplasty in a randomized prospective trial comparing fondaparinux with enoxaparin. Knee 2006; 13: 118-121.
    CrossrefPubMedGoogle Scholar
  • 35 Planes A, Vochelle N, Mazas F. et al. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb Haemost 1988; 60: 407-410.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 36 Faunø P, Suomalainen O, Rehnberg V. et al. Prophylaxis for the prevention of venous thromboembolism after total knee arthroplasty. A comparison between unfractionated and low-molecular-weight heparin. J Bone Joint Surg Am 1994; 76: 1814-1818.
    CrossrefPubMedGoogle Scholar
  • 37 Perhoniemi V, Vuorinen J, Myllynen P. et al. The effect of enoxaparin in prevention of deep venous thrombosis in hip and knee surgery--a comparison with the dihydroergotamine-heparin combination. Ann Chir Gynaecol 1996; 85: 359-363.
    PubMedGoogle Scholar
  • 38 Rader CP, Kramer C, König A. et al. Low-molecular-weight heparin and partial thromboplastin time-adjusted unfractionated heparin in thromboprophylaxis after total knee and total hip arthroplasty. J Arthroplasty 1998; 13: 180-185.
    CrossrefPubMedGoogle Scholar
  • 39 Avikainen V, von Bonsdorff H, Partio E. et al. Low molecular weight heparin (enoxaparin) compared with unfractionated heparin in prophylaxis of deep venous thrombosis and pulmonary embolism in patients undergoing hip replacement. Ann Chir Gynaecol 1995; 84: 85-90.
    PubMedGoogle Scholar
  • 40 Senaran H, Acaroğlu E, Ozdemir HM. et al. Enoxaparin and heparin comparison of deep-vein thrombosis prophylaxis in total hip replacement patients. Arch Orthop Trauma Surg 2006; 126: 1-5.
    CrossrefPubMedGoogle Scholar
  • 41 Warwick D, Bannister GC, Glew D. et al. Perioperative low-molecular-weight heparin. Is it effective and safe. J Bone Joint Surg Br 1995; 77: 715-719.
    PubMedGoogle Scholar
  • 42 Kalodiki EP, Hoppensteadt DA, Nicolaides AN. et al. Deep venous thrombosis prophylaxis with low molecular weight heparin and elastic compression in patients having total hip replacement. A randomised controlled trial. Int Angiol 1996; 15: 162-168.
    PubMedGoogle Scholar
  • 43 Samama CM, Clergue F, Barre J. et al. Low molecular weight heparin associated with spinal anaesthesia and gradual compression stockings in total hip replacement surgery. Arar Study Group. Br J Anaesth 1997; 78: 660-665.
    CrossrefPubMedGoogle Scholar
  • 44 Fuji T, Ochi T, Niwa S. et al. Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin. J Orthop Sci 2008; 13: 442-451.
    CrossrefPubMedGoogle Scholar
  • 45 Lassen MR. Is the preoperative administration of enoxaparin 40 mg necessary to optimally prevent the occurrence of venous thromboembolism after hip surgery? A subanalysis of two pooled randomized trials. J Thromb Haemost 2009; 07: 889-891.
    CrossrefPubMedGoogle Scholar
  • 46 Strebel N, Prins M, Agnelli G. et al. Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery?. Arch Intern Med 2002; 162: 1451-1456.
    CrossrefPubMedGoogle Scholar
  • 47 Eikelboom JW, Quinlan DJ, O’Donnell M. Major bleeding, mortality, and efficacy of fondaparinux in venous thromboembolism prevention trials. Circulation 2009; 120: 2006-2011.
    CrossrefPubMedGoogle Scholar
  • 48 Edwards SJ, Clarke MJ, Wodsworth S. et al. Indirect comparisons of treatments based on systematic reviews of randomised controlled trials. Int J Clin Prac 2009; 63: 841-854.
    CrossrefPubMedGoogle Scholar
  • 49 Song F, Harvey I, Lilford R. Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions. J Clin Epidemiol 2008; 61: 455-463.
    CrossrefPubMedGoogle Scholar
  • 50 Kwok CS, Pradhan S, Yeong JK. et al. Relative effects of two different enoxaparin regimens as comparators against newer oral anticoagulants: meta-analysis and adjusted indirect comparison. Chest 2013; 144: 593-600.
    CrossrefPubMedGoogle Scholar